HIV DIVERSITY CONSEQUENCES FOR PUBLIC HEALTH

3.68. F. 5.38. 5.36. 5.6. G. 4.3. 4.44. 4.73. G. 4.96. 4.06. 3.55. Subtypes and viral load ... p = 0.78. 4.52±4.3. 0.91±1.21 p = 0.002. 2nd Generation EIA. OD SAM. P.
375KB taille 13 téléchargements 302 vues
HIV DIVERSITY CONSEQUENCES FOR PUBLIC HEALTH

CENTRE HOSPITALIER UNIVERSITAIRE FACULTÉ DE MÉDECINE ROUEN

Professeur F. Simon

Docteur JC. Plantier

22 octobre 2002

THE PRIMATE LENTIVIRUSES DIVERSITY

• Non-human primates : > 18 different species reported as siv-infected • Human : 2 types of hiv as consequence of different crossspecies transmission

INTRODUCTION : Primates Lentiviruses (1996)

HIV-O

SIVcpz

CPZANT HIV-M ( A to H) SIV AGM

SIV agm sab SIV Mnd

SIV sm

HIV-2

INTRODUCTION : Primates Lentiviruses (2000) HIV-0 : A

HIV-O : B CPZCam/ HIV-N

CPZANT SIVrcm

HIV-M (A to K)

SIVsyk SIV Mnd Type 2 SIVagm

SIV drill

SIV Mnd Type 1 SIVsun

SIV AGM sab SIVhoe

SIV sm

HIV-2

INTRODUCTION : HIV-1

GROUP M GROUP N GROUP O

3 LINEAGES

: > 306 of cases; 11 subtypes ( A to K) : only six cases so far reported : > 500 cases ; cladistic organisation

EACH HIV-1 GROUP WOULD CORRESPOND TO INDEPENDANT TRANSMISSION OF SIVCPZ FROM CHIMPANZEE TO HUMAN

INTRODUCTION : HIV-2

A B C to G

‘ SUBTYPES ‘ (or groups ??)

: West Africa, Atlantic coast : Mali, Ivory Coast : Liberia, Sierra Leone : dead-end infections

EACH HIV- 2 SUBTYPE WOULD CORRESPOND TO INDEPENDANT TRANSMISSION OF SIVsm FROM SOOTY MANGABEYS TO HUMAN

HIV variability - High replication and mutation rate of HIV combined with the genomic integration and dormancy - half -life of plasma virion < 6 hours, 10 billions virions produced each day - RT pol-encoded lacks exonuclease activity : 1 mutation occurs each replication cycle - complex of genitically related but distinguishable variants =

HIV = QUASISPECIES

HIV diversity and epidemiology

Subtype : env gene homology > 80% - subtypes are reflecting a founder effect in a particular population like subtype B in IVDU , F in Romanian children, G in Russia - no clear founder effect in Africa / predominance of the heterosexual transmission ? - frequency of the circulating recombinant forms (CRF) 50% of the strains sequenced in Gabon in 2000 are CRF. Epidemiological advantage ??

A new strategy for Siv/hiv characterization Anti-hiv/siv antibodies detection using Synthetic peptides in 2 eias :

- First eia : highly sensitive Gp 41 id from hiv-m/n/o, sivcpz/agm/mnd/sm…

- Second eia : highly specific

V3 loop from hiv-m/n/o, sivcpz/agm/mnd/sm… Each sample is tested by at least 16 peptides

Reactive samples : RT-PCR and amplification using degenerated primers and pol sequencing

Hiv and siv detection and differenciation by synthetic peptides

peptides V3 or gp41 M HIV-1

O N cpz-gab

SIV

cpz-ant mnd agm sm

Specificity of V3 loop peptide-based EIAs

group M sera (n=142)

M

O

N

Cpz

Mnd Agm

Sm

group N sera (n=6)

M

O

N

Cpz

Mnd Agm

Sm

N

Cpz

Mnd Agm

Sm

HIV-2 sera (n=150)

group O sera (n=56)

M

O

M

O

N

Cpz

Mnd Agm

Sm

PCR strategy ; HIV and SIV pol gene amplification POL CAM 50 450 LENTIPOL S ET AS 1020

UNIPOL3 1940

POL CAM 52 POL LUP S 1120 POL LUP AS 900 1020

MP2

MP5

UNIPOL1 2420

UNIPOL 2 2700

H POL 4235 2570

MP3

UNIPOL4 2900 H POL 4538

H POL 4327 2650

H POL 4481 2800

MP6

More than 10 sets of primers (including highly de generated primers) needed to successfully amplified the 3 ’ pol

HIV-1 DIVERSITY SURVEY IN FRANCE A NATIONAL ANRS NETWORK

• 32 laboratories • 3000 HIV-1 infected patient serotyped and genotyped

17% of non-B infection in France 25 % of non-B in Paris area All the subtypes ( A to K) are represented Importance of the heterosexual transmission

HIV-1 diversity survey in france A national anrs network

• subtype B : still predominant in homo/bisexual and IVDU • incidence of non-B in France < 1996 : 10 % >1996: 21 % • HIV-1 non B 46% of heterosexual infection 90% of African patients /partners •frequency of the circulating recombinant form (CRF) in non-B •report of gag non-B and env- B CRF

Subtypes and viral load

106

Monitor/Monitor 1.5 (Eq/ml)

105

104 103

102

10

1 1

10

102

103

104

105

106

bDNA (Eq/ml) • Monitor

o

Monitor 1.5

107

VIH-1 subtype B B B B B B B B B B B B A A A A A A A A A A A A A A A A A A D D E F G G

bDNA Monitor

3.94 4.88 4.57 2.85 5.25 3.42 4.67 6.43 4.63 5.65 5.43 4.98 4.67 5.09 4.53 4.7 5.64 6.14 2.71 4.25 3.4 5.38 4.3 4.96